Clinical Trials
Genentech Phase II study shows Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor
Genentech, a member of the Roche Group announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination...
Clinical Trials
Novartis study shows drug Afinitor plus hormonal therapy delays disease progression in advanced metastatic breast cancer patients
A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor...
Clinical Trials
Phase III study showed Rituxan/MabThera decreased the risk of needing later treatment with chemotherapy or radiotherapy by 80% by Roche
Roche announced positive data from a Phase III study of Rituxan/MabThera (rituximab) in patients with advanced follicular lymphoma who did not have symptoms of disease...
Clinical Trials
QR Pharma receives FDA clearance to conduct clinical trials with its second novel Alzheimer compound
QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced today that the United States Food and Drug Administration (FDA)...
Clinical Trials
Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies
Bayer HealthCare and Regeneron Pharmaceuticals, Inc. announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet...
Clinical Trials
Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl
Abbott Park, Illinois-Reata Pharmaceuticals and Abbott today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney...
Clinical Trials
Novartis discontinues ASA404 clinical trial program and shifts focus to other cancer compounds in early and late stage development
Novartis announced that the clinical trial program for the investigational cancer treatment ASA404 (vadimezan) will be discontinued and resources will be reallocated to other compounds...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.